<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03617471</url>
  </required_header>
  <id_info>
    <org_study_id>S58396 - mp05485</org_study_id>
    <nct_id>NCT03617471</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Paracetamol in Patients Over 80 Years Hospitalized to an Acute Geriatric Ward</brief_title>
  <official_title>Pharmacokinetic Study of Paracetamol in Patients Over 80 Years Hospitalized to an Acute Geriatric Ward</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this exploratory study is the characterization of the pharmacokinetic profile of
      paracetamol in older patients and the specific PK variables associated with plasma exposure
      in this population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this exploratory study is the characterization of the pharmacokinetic profile of
      paracetamol in older patients and the specific PK variables associated with plasma exposure
      in this population. The primary endpoint is the identification of the pharmacokinetic
      parameters: area under the curve (AUC), peak plasma concentration after administration of
      paracetamol (Cmax) and the time at which the Cmax is observed (Tmax) of paracetamol. The
      secondary endpoint consists of 3 sub-endpoints:

        1. The variability in plasma exposure: volume of distribution (Vd), clearance (Cl) and
           elimination half-life (t1/2)

        2. The association between the PK parameters and pathophysiological factors

        3. The correlation between PK parameters and clinical parameters.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of the pharmacokinetic parameters: AUC</measure>
    <time_frame>8 hours (= during 1 dosing interval at steady state)</time_frame>
    <description>Area under the curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of the pharmacokinetic parameters: Cmax</measure>
    <time_frame>8 hours (= during 1 dosing interval at steady state)</time_frame>
    <description>Peak plasma concentration after administration of paracetamol (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of the pharmacokinetic parameters: Tmax</measure>
    <time_frame>8 hours (= during 1 dosing interval at steady state)</time_frame>
    <description>The time at which the Cmax is observed (Tmax) of paracetamol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variability in plasma exposure: Vd</measure>
    <time_frame>8 hours (= during 1 dosing interval at steady state)</time_frame>
    <description>Volume of distribution (Vd)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability in plasma exposure: t1/2</measure>
    <time_frame>8 hours (= during 1 dosing interval at steady state)</time_frame>
    <description>Elimination half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability in plasma exposure: Cl</measure>
    <time_frame>8 hours (= during 1 dosing interval at steady state)</time_frame>
    <description>Clearance (Cl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The association between the AUC (area under the curve) of paracetamol and patient related factors.</measure>
    <time_frame>8 hours (= during 1 dosing interval at steady state)</time_frame>
    <description>Multivariate analysis will be performed with AUC (area under the curve) as outcome. This will allow to identify variables influencing AUC of paracetamol. Patient related factors include amongst others age, weight, albumin, bilirubin, serum creatinin and co medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The association between the AUC (area under the curve) of paracetamol and pain scores.</measure>
    <time_frame>8 hours (= during 1 dosing interval at steady state)</time_frame>
    <description>Pain scores will be based on the Numeric Rating Scale with a score of 0 indicating no pain and a score of 10 indicating worst imaginable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between immuno assay method and the Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to determine paracetamol concentrations in serum</measure>
    <time_frame>8 hours (= during 1 dosing interval at steady state)</time_frame>
    <description>Correlation between two different assays will be determined through Bland Altman statistics.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Paracetamol oral tablets 1g tid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received paracetamol one gram three times daily. Venopuncture for PK profiling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paracetamol oral granules 1g tid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received paracetamol one gram three times daily. Venopuncture for PK profiling</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Venopuncture for PK profiling</intervention_name>
    <description>Blood samples at T0, T0.5, T1, T2, T4, T6</description>
    <arm_group_label>Paracetamol oral granules 1g tid</arm_group_label>
    <arm_group_label>Paracetamol oral tablets 1g tid</arm_group_label>
    <other_name>Blood sampling for paracetamol dosage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a minimum age of 80 years

          -  admission to the acute geriatrics ward

          -  oral intake of paracetamol 1000 milligram (mg) in tablet form tid

          -  a steady state situation (defined as at least 4 consecutive intakes of paracetamol
             before sampling)

        Exclusion Criteria:

          -  palliative care setting with downgrading of care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>80 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabel Spriet, PharmD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>November 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>July 31, 2018</last_update_submitted>
  <last_update_submitted_qc>July 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Isabelle Spriet</investigator_full_name>
    <investigator_title>PharmD PhD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

